Skip to main content

Table 2 Subgroup analysis

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

Subgroup category OR rate CR rate RR
Study, n ORR (95% CI) I2 (%) Study, n CRR (95% CI) I2 (%) Study, n RR (95% CI) I2 (%)
Overall 37 0.84 (0.80, 0.88) 75.76 37 0.61 (0.49, 0.73) 97.46 32 0.21 (0.15, 0.26) 75.73
Study design
 Clinical trial 13 0.80 (0.72, 0.89) 83.81 13 0.56 (0.32, 0.80) 98.54 11 0.15 (0.07, 0.22) 73.10
 Observational study 24 0.85 (0.80, 0.89) 69.89 24 0.64 (0.51, 0.76) 95.79 21 0.23 (0.17, 0.30) 72.29
Diagnosis
 AIHA 24 0.79 (0.73, 0.84) 73.20 24 0.44 (0.33, 0.55) 93.13 19 0.28 (0.20, 0.36) 76.36
 wAIHA 8 0.79 (0.69, 0.90) 75.89 8 0.49 (0.22, 0.77) 96.27 7 0.31 (0.14, 0.47) 82.22
 CAD 5 0.66 (0.57, 0.76) 45.99 5 0.14 (0.03, 0.25) 82.57 4 0.31 (0.10, 0.53) 81.81
 MAHA 13 0.93 (0.89, 0.97) 46.99 13 0.93 (0.89, 0.97) 46.99 13 0.09 (0.05, 0.13) 29.13
 TTP 12 0.92 (0.88, 0.96) 50.74 12 0.92 (0.88, 0.96) 50.74 12 0.08 (0.04, 0.12) 21.38
 HUS 1 0.97 (0.88, 1.06)   1 0.97 (0.88, 1.06)   1 0.29 (0.05, 0.52)  
Dosage regimen
 375 mg/m2 4 weekly 28 0.83 (0.78, 0.88) 78.64 28 0.62 (0.48, 0.77) 98.03 24 0.20 (0.14, 0.26) 77.50
 Other regimen 8 0.84 (0.76, 0.91) 67.49 8 0.56 (0.45, 0.67) 70.80 7 0.24 (0.13, 0.32) 72.87
Treatment modalities of AIHA
 RTX alone 14 0.82 (0.76, 0.88) 72.74 14 0.44 (0.29, 0.59) 93.22 12 0.30 (0.20, 0.40) 78.27
 In combination 10 0.74 (0.66, 0.81) 59.22 10 0.45 (0.27, 0.63) 93.70 7 0.26 (0.12, 0.39) 76.19